Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.42 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10327379 | 0.91 | CPA3 (0.50) | FFAR1CYP1A2ANPEP | |
| SCHEMBL5368777 | 0.89 | CYP1A2 (0.47) | FFAR1TDP1L3MBTL1CYP1A2CYP2A6 | |
| SCHEMBL17590311 | 0.82 | TSHR (0.50) | FFAR1TDP1L3MBTL1SMN1; SMN2CYP1A2 | |
| SCHEMBL11825954 | 0.82 | S1PR2 (0.47) | FFAR1TDP1L3MBTL1SMN1; SMN2CYP1A2 | |
| SCHEMBL25181550 | 0.82 | TSHR (0.50) | FFAR1TDP1L3MBTL1SMN1; SMN2CYP1A2 | |
| SCHEMBL1857365 | 0.81 | CYP1A2 (0.61) | CYP1A2ANPEP | |
| SCHEMBL16315019 | 0.81 | CYP1A2 (0.45) | FFAR1TDP1L3MBTL1SMN1; SMN2CYP1A2 | |
| SCHEMBL16148061 | 0.81 | KIF11 (0.54) | FFAR1TDP1L3MBTL1CYP1A2CYP2A6 | |
| SCHEMBL11827938 | 0.81 | FFAR1 (0.45) | FFAR1TDP1L3MBTL1SMN1; SMN2CYP1A2 | |
| SCHEMBL16148063 | 0.81 | KIF11 (0.54) | FFAR1TDP1L3MBTL1CYP1A2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985876-B2 | Substituted dibenzoic acid derivatives and use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-26 | — | — | US | disclosed |
| US-20100168240-A1 | SUBSTITUTED DIBENZOIC ACID DERIVATIVES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168240-A1 | SUBSTITUTED DIBENZOIC ACID DERIVATIVES AND USE THEREOF | BBOX1, DDC, DDT | FFAR1 417/4885TDP1 1039/4885L3MBTL1 2527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.